Lynn Sage Foundation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2012
NCT01730729
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

cabergoline (dostinex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1